Scholarlink

Background <p>Diagnostic work-up of patients with hypertrophic cardiomyopathy is crucial for appropriate management. However, the optimal genetic strategy remains debatable. We compared two strategies: targeted testing based on careful examination of clinical red flags versus large multigene panel analysis without gene prioritization. We applied the strategy to the diagnosis of Fabry disease or Hereditary Transthyretin Amyloidosis (<i>GLA</i> or <i>TTR</i> genes respectively).</p> Results <p>We studied 341 hypertrophic cardiomyopathy index patients. Patients of subgroup 1 (n = 42) had careful clinical analysis and high suspicion of Hereditary Transthyretin Amyloidosis or Fabry disease. They underwent targeted Sanger sequencing. Patients in subgroup 2 (n = 299) did not have clinical selection, and underwent next-generation sequencing analysis of 107 cardiac genes.</p> <p>The yield of genetic testing for pathogenic/likely pathogenic variants in <i>GLA</i> and/or <i>TTR</i> was 28.6% in subgroup 1 (12/42: 5 <i>TTR</i> and 7 <i>GLA</i>) versus 1.0% in subgroup 2 (3/299: 1 <i>TTR</i> and 2 <i>GLA</i>), <i>p</i> &lt; 0.01. Genetic results were obtained after a median of 26.0&#xa0;days [IQR = 18–59.8] in subgroup 1 versus 193.5&#xa0;days [IQR = 174–218] in subgroup 2, <i>p</i> &lt; 0.01. Finally, genetic testing cost was 615.60€ or 769.50€ for <i>TTR</i> or <i>GLA</i> targeted analysis respectively, versus 1503.90€ for multigene panel analysis.</p> Conclusions <p>Both molecular strategies in hypertrophic cardiomyopathy patients are useful for the identification of pathogenic/likely pathogenic variants in <i>TTR/GLA</i> genes. However, targeted genetic testing based on clinical red flags identified causal mutations more efficiently, faster and at a lower cost. Careful clinical analysis is therefore important in guiding molecular strategy and may reduce diagnostic wandering and accelerate delivery of appropriate therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of two genetic strategies for diagnostic work-up of hypertrophic cardiomyopathy: impact on the diagnosis of Fabry disease or transthyretin amyloidosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月10日

查看全文
  • Aurélien Palmyre,
  • Fairouz Koraichi,
  • Flavie Ader,
  • Erwan Donal,
  • Céline Bordet,
  • Pascal de Groote,
  • Laurence Faivre,
  • Patricia Reant,
  • Annick Toutain,
  • Karine Nguyen,
  • Bertrand Isidor,
  • Anne-Claire Brehin,
  • Lise Legrand,
  • Estelle Gandjbakhch,
  • Julie Proukhnitzky,
  • Richard Isnard,
  • Nicolas Mansencal,
  • Jean-François Pruny,
  • Jean-Pierre Rabes,
  • Bruno Francou,
  • Catherine Caillaud,
  • Pascale Richard,
  • Philippe Charron

摘要

Background

Diagnostic work-up of patients with hypertrophic cardiomyopathy is crucial for appropriate management. However, the optimal genetic strategy remains debatable. We compared two strategies: targeted testing based on careful examination of clinical red flags versus large multigene panel analysis without gene prioritization. We applied the strategy to the diagnosis of Fabry disease or Hereditary Transthyretin Amyloidosis (GLA or TTR genes respectively).

Results

We studied 341 hypertrophic cardiomyopathy index patients. Patients of subgroup 1 (n = 42) had careful clinical analysis and high suspicion of Hereditary Transthyretin Amyloidosis or Fabry disease. They underwent targeted Sanger sequencing. Patients in subgroup 2 (n = 299) did not have clinical selection, and underwent next-generation sequencing analysis of 107 cardiac genes.

The yield of genetic testing for pathogenic/likely pathogenic variants in GLA and/or TTR was 28.6% in subgroup 1 (12/42: 5 TTR and 7 GLA) versus 1.0% in subgroup 2 (3/299: 1 TTR and 2 GLA), p < 0.01. Genetic results were obtained after a median of 26.0 days [IQR = 18–59.8] in subgroup 1 versus 193.5 days [IQR = 174–218] in subgroup 2, p < 0.01. Finally, genetic testing cost was 615.60€ or 769.50€ for TTR or GLA targeted analysis respectively, versus 1503.90€ for multigene panel analysis.

Conclusions

Both molecular strategies in hypertrophic cardiomyopathy patients are useful for the identification of pathogenic/likely pathogenic variants in TTR/GLA genes. However, targeted genetic testing based on clinical red flags identified causal mutations more efficiently, faster and at a lower cost. Careful clinical analysis is therefore important in guiding molecular strategy and may reduce diagnostic wandering and accelerate delivery of appropriate therapy.